Unknown

Dataset Information

0

Adjunctive perampanel for glioma-associated epilepsy.


ABSTRACT: Glioma-associated epilepsy is associated with excessive glutamate signaling. We hypothesized that perampanel, an amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist, would treat glioma-related epilepsy. We conducted a single-arm study of adjunctive perampanel for patients with focal-onset glioma-associated seizures. The most common related adverse events were fatigue and dizziness. Three out of 8 participants had self-reported seizure reduction and an additional 3 reported improved control. Of these 6, 5 had isocitrate dehydrogenase 1 mutant gliomas. We conclude that perampanel is safe for patients with glioma-related focal-onset epilepsy. Further study into the association between AMPA signaling, IDH1 status and seizures is warranted.

SUBMITTER: Dunn-Pirio AM 

PROVIDER: S-EPMC6202665 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications


Glioma-associated epilepsy is associated with excessive glutamate signaling. We hypothesized that perampanel, an amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist, would treat glioma-related epilepsy. We conducted a single-arm study of adjunctive perampanel for patients with focal-onset glioma-associated seizures. The most common related adverse events were fatigue and dizziness. Three out of 8 participants had self-reported seizure reduction and an add  ...[more]

Similar Datasets

| S-EPMC8290415 | biostudies-literature
| S-EPMC6444512 | biostudies-literature
| S-EPMC5457730 | biostudies-literature
| S-EPMC4785606 | biostudies-literature
| S-EPMC3413761 | biostudies-literature
| S-EPMC4150630 | biostudies-literature
| S-EPMC8150827 | biostudies-literature
| S-EPMC6436628 | biostudies-literature
| S-EPMC4567458 | biostudies-literature
| S-EPMC4433458 | biostudies-literature